On August 6, 2020, Bausch Health Companies Inc. announced its intention to spin off its eye health business into an independent publicly traded company from the remainder of Bausch Health. The separation will create two separate companies including a fully integrated, pure play eye health company and a diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology and international pharmaceuticals. The benefits of separating these attractive but disparate businesses include improved strategic focus and enhanced financial transparency to better enable stakeholders to value each business independently.
Bausch Health Companies is a global health company focused on the development, manufacturing and marketing of a range of pharmaceutical, medical device and over the counter products in the areas of health, gastroenterology and dermatology.
Osler, Hoskin & Harcourt LLP is advising Bausch Health Companies Inc. with a team led by Douglas Marshall and John Valley (Corporate).